Kancera today reports that the company has submitted the regulatory application to conduct a First-In-Human study of its Fractalkine blocker KAND145.
Read MoreKancera AB (publ) today announces that it has submitted the regulatory application to the Swedish Medical Products Agency to conduct clinical studies of KAND567 in ovarian cancer and entered into an agreement with the Nordic Society of Gynaecological Oncology...
Read MoreKancera AB (publ) reports new preclinical results supporting the potential for KAN571, a ROR1 inhibitor, for treatment of mantle cell lymphoma (MCL), a subtype of B-cell malignancies. Preclinical studies of KAN571 in MCL cell lines show that KAN571 effectively...
Read MoreKancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).
Read MoreKancera AB (publ) is today reporting that patient recruitment to the ongoing phase IIa study of KAND567 in myocardial infarction patients is progressing well and 54 patients of the targeted 60 patients have been enrolled so far. The company...
Read MoreKancera AB (publ) is today reporting new results that confirm that the company’s Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer. As a result, Kancera has met...
Read MoreKancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera's fractalkine blocker KAND145. This patent, US 11,339,183, is owned by Kancera and is valid through 2039.
Read MoreKancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.
Read Moretwo thirds of patients have now been dosed in the clinical study of KAND567 for the treatment of COVID-19; patient recruitment is expected to be completed during the current quarter, successful scaling up of production of the drug candidate...
Read MoreKancera AB (Nasdaq First North Premier Growth Market: KAN) reports preclinical research results, which show that the company's Fractalkine blockers have the potential to disrupt cancer cells' resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer...
Read More